Sorafenib Prophylaxis Is Effective in Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients

被引：0
|
作者：
Saab, Sammy [1 ]
McTigue, Mike [1 ]
Finn, Richard [1 ]
Busuttil, Ronald W. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
LIVER TRANSPLANTATION | 2010年 / 16卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [1] Sorafenib in Liver Transplant (LT) Recipients at High Risk of Hepatocellular Carcinoma (HCC) Recurrence
    Yan, W.
    Agrawal, N.
    Gadwale, G.
    Laurin, J.
    Satoskar, R.
    Manzanares, K.
    He, R.
    Johnson, L.
    Fishbein, T.
    Shetty, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 113 - 113
  • [2] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant
    Mancuso, Andrea
    TRANSPLANTATION, 2020, 104 (08) : E243 - E243
  • [3] Role of mTOR inhibitor in liver transplant recipients administering sorafenib for advanced hepatocellular carcinoma recurrence
    Jung, D. -H.
    Tak, E.
    Hwang, S.
    Kim, K. -H.
    Ahn, C-S.
    Moon, D. -B.
    Ha, T. -Y.
    Song, G. -W.
    Park, G. -C.
    Lee, S. -G.
    TRANSPLANTATION, 2018, 102 : 277 - 277
  • [4] Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
    Hussaarts, Koen G. A. M.
    van Doorn, Leni
    Bins, Sander
    Sprengers, Dave
    de Bruijn, Peter
    van Leeuwen, Roelof W. F.
    Koolen, Stijn L. W.
    van Gelder, Teun
    Mathijssen, Ron H. J.
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 10
  • [5] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant Reply
    Invernizzi, Federica
    Iavarone, Massimo
    TRANSPLANTATION, 2020, 104 (08) : E244 - E244
  • [6] Nivolumab after sorafenib failure in liver recipients with hepatocellular carcinoma recurrence
    Kwon, J.
    Park, S.
    Yun, S. O.
    Yang, J.
    Lim, M.
    Rhu, J.
    Choi, G. -S.
    Kim, J. M.
    Joh, J. -W.
    TRANSPLANTATION, 2023, 107 (09) : 265 - 265
  • [7] Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era
    Pfiffer, Tulio E. F.
    Seehofer, Daniel
    Nicolaou, Annett
    Neuhaus, Ruth
    Riess, Hanno
    Trappe, Ralf U.
    TUMORI JOURNAL, 2011, 97 (04): : 436 - 441
  • [8] HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence
    Karasu, Z
    Ozacar, T
    Akarca, U
    Ersoz, G
    Erensoy, S
    Gunsar, F
    Kobat, A
    Tokat, Y
    Batur, Y
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (02) : 212 - 215
  • [9] Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
    Shetty, Kirti
    Dash, Chiranjeev
    Laurin, Jacqueline
    JOURNAL OF TRANSPLANTATION, 2014, 2014
  • [10] High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients
    Nitta, Hidetoshi
    Younes, Aline
    El-domiaty, Nada
    Karam, Vincent
    Sobesky, Rodolphe
    Vibert, Eric
    Coilly, Audrey
    Maria Antonini, Teresa
    De Martin, Eleonora
    Cherqui, Daniel
    Baba, Hideo
    Rosmorduc, Olivier
    Adam, Rene
    Samuel, Didier
    Saliba, Faouzi
    TRANSPLANT INTERNATIONAL, 2021, 34 (07) : 1293 - 1305
12345